Courage Capital Management’s Galectin Therapeutics GALT Stock Holding History

Courage Capital Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22,126	Closed	-$141K	–	28
2018 Q2	$141K	Sell	22,126 -7,874	-26%	-$38.4K	0.11%	24
2018 Q1	$142K	Sell	30,000 -20,000	-40%	-$93.2K	0.11%	28
2017 Q4	$167K	Sell	50,000 -80,000	-62%	-$202K	0.12%	23
2017 Q3	$278K	Hold	130,000	–	–	0.19%	17
2017 Q2	$320K	Hold	130,000	–	–	0.16%	17
2017 Q1	$299K	Hold	130,000	–	–	0.25%	14
2016 Q4	$127K	Hold	130,000	–	–	0.08%	18
2016 Q3	$147K	Buy	+130,000	New	+$231K	0.06%	16

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Courage Capital Management's GALT Position: Q3 2018 in Review

Courage Capital Management sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 22,126 shares — an estimated $141K sold.

Courage Capital Management first reported a position in GALT in Q3 2016 and held it in 8 quarters. The position peaked at $320K in Q2 2017. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

Courage Capital Management reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
Courage Capital Management sold 22,126 Galectin Therapeutics shares in Q3 2018, an estimated $141K.
Courage Capital Management first reported a position in Galectin Therapeutics in Q3 2016 and held it in 8 quarters.
Courage Capital Management's Galectin Therapeutics position peaked at $320K in Q2 2017.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on Courage Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.